- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05788887
Investigation of the Postprandial Response of Two Different PDO Cheeses on Metabolic Biomarkers (LadotyriCT)
April 11, 2023 updated by: ANTONIOS KOUTELIDAKIS, University of the Aegean
Postprandial Inflammatory and Metabolic Responses Induced by the Authentic Ladotyri Mytilinis PDO Cheese and Italian Parmesan PDO Cheese
The purpose of this study was the investigation of the postprandial metabolic responses, after the intake of a traditional, Ladotyri Mytilinis cheese, compared to corresponding responses after an Italian Parmesan cheese consumption, in healthy participants.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
A pilot cross-over, randomized and single-blinded, intervention-clinical trial was conducted, in ten healthy men and women subjects, aged eighteen to thirty years, after random allocation into the control and the intervention group, received a high-fat and carbohydrates meal, containing Ladotyri Mytilinis (the authentic nonrefrigerated recipe) or Italian Parmesan, PDO cheeses.
After a washout week, participants consumed the same meals, conversely.
Differences on postprandial responses of serum total, High Density Lipoprotein (HDL-), Low Density Lipoprotein (LDL-) cholesterol, glucose, triglycerides and uric acid levels, as well as of plasma total antioxidant capacity according to Ferric Reducing Antioxidant Power method, were determined between groups in fasting, thirty minutes, one and a half hour, and three hours after meal intake.
Study Type
Interventional
Enrollment (Actual)
10
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Myrina, Greece, 81 400
- University of the Aegean
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- Age 18-65 years
- Willingness to join and complete the nutritional intervention
Exclusion Criteria:
- Inability or unwillingness to provide informed consent
- Three-month nutritional supplement
- Age over 65 years or below 18 years
- Chronic diseases history
- Hemoglobin A1c - HbA1c > 5.7 %
- Abnormal Body Mass Index (BMI) (> 25 kg / m2)
- Abnormal hematological or biochemical profile (total cholesterol > 240 mg/dL, triglycerides > 250 mg/dL, glucose > 100 mg/dL)
- Alcohol overdose (> 40 g alcohol / day)
- Heavy smoking (> 10 cigarettes / day)
- Concurrent participation in another intervention study or unconsciousness in previous blood draws
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Placebo Comparator: Control
The meal contained 100g of white wheat bread and 80g of Italian Parmesan PDO cheese.
|
Branding Parmesan PDO cheese from Italy, supplied by LIDL Hellas
Other Names:
|
|
Other: Intervention
The meal contained 100g of white wheat bread and 80g of Authentic Ladotyri Mytilinis PDO cheese.
|
Branding PDO cheese from Mytilini, purchasing by E.Thimelis Dairy S.A.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Changes from baseline of Total Antioxidant Capacity at 30 minutes, 1.5 hours and 3 hours
Time Frame: 3 hours
|
Plasma antioxidant activity
|
3 hours
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Changes from baseline of total Cholesterol at 30 minutes, 1.5 hours and 3 hours
Time Frame: 3 hours
|
Serum total cholesterol levels
|
3 hours
|
|
Changes from baseline of High Density Lipoprotein cholesterol (HDL-) at 30 minutes, 1.5 hours and 3 hours
Time Frame: 3 hours
|
Serum High Density Lipoprotein levels
|
3 hours
|
|
Changes from baseline of Low Density Lipoprotein cholesterol (LDL-) at 30 minutes, 1.5 hours and 3 hours
Time Frame: 3 hours
|
Serum High Density Lipoprotein levels
|
3 hours
|
|
Changes from baseline of triglycerides at 30 minutes, 1.5 hours and 3 hours
Time Frame: 3 hours
|
Serum triglycerides levels
|
3 hours
|
|
Changes from baseline of glucose at 30 minutes, 1.5 hours and 3 hours
Time Frame: 3 hours
|
Serum glucose levels
|
3 hours
|
|
Changes from baseline of Uric Acid at 30 minutes, 1.5 hours and 3 hours
Time Frame: 3 hours
|
Serum uric acid levels
|
3 hours
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 10, 2022
Primary Completion (Actual)
January 17, 2022
Study Completion (Actual)
January 17, 2022
Study Registration Dates
First Submitted
February 24, 2023
First Submitted That Met QC Criteria
March 16, 2023
First Posted (Actual)
March 29, 2023
Study Record Updates
Last Update Posted (Actual)
April 14, 2023
Last Update Submitted That Met QC Criteria
April 11, 2023
Last Verified
April 1, 2023
More Information
Terms related to this study
Other Study ID Numbers
- BAP20060569
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
IPD Plan Description
No individual participant data are to be shared.
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.